The HemOnc Pulse
By Rahul Banerjee, MD
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by Rahul Banerjee, MD
Category: Science
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 2
Reviews: 0
Episodes: 84
Description
Blood Cancers Today and the Society of Hematologic Oncology bring you The HemOnc Pulse, a podcast hosted by Rahul Banerjee, MD, covering all topics in the world of hematologic oncology.
| Episode | Date |
|---|---|
|
Cutting GVHD Risk: What’s Changing in Allogeneic Transplants?
|
Mar 30, 2026 |
|
MRD at the Regulatory Crossroads in Multiple Myeloma
|
Feb 07, 2026 |
|
The Data Problem in T-Cell Lymphoma Care
|
Jan 27, 2026 |
|
XPO1 Inhibition Across the Myeloma Journey
|
Dec 26, 2025 |
|
Holding the Line in AML: Real-World Care Meets Breakthrough Trials
|
Dec 20, 2025 |
|
Under the Hood: Exploring the Genomic Engines of Smoldering Myeloma
|
Oct 17, 2025 |
|
Toxicity, Time, and the Patient Experience in Blood Cancers
|
Oct 03, 2025 |
|
Editor's Special Episode: Future Directions in MPN Treatment with Dr. Hobbs
|
Oct 01, 2025 |
|
Clinical Advances in Myeloma: A Nordic Perspective
|
Sep 12, 2025 |
|
Grand Rounds in Leukemia: MD Anderson Fellows on AML Endpoints
|
Sep 07, 2025 |
|
Editor’s Special Episode: Progress and Prospects in CLL Management
|
Aug 27, 2025 |
|
Today’s Clinical Trials Define the Next Era in Myeloma
|
Aug 22, 2025 |
|
‘The HemOnc Pulse Live:’ Transforming ALL Treatment Pathways
|
Aug 15, 2025 |
|
Evolving Approaches in the Management of MDS
|
Aug 08, 2025 |
|
‘The HemOnc Pulse Live!’: AML in Transition
|
Aug 01, 2025 |
|
From Trials to Practice: What's New and What's Next for Myeloma
|
Jul 25, 2025 |
|
Editor’s Special Episode: Innovations in B-NHL
|
Jul 18, 2025 |
|
Editor’s Special Episode: Treating CLL Now and in the Future
|
Jul 14, 2025 |
|
'The HemOnc Pulse Live': Controversies in Frontline Myeloma
|
Jul 03, 2025 |
|
Editor’s Special Episode: ASCO 2025 Highlights in AML with Dr. Amir Fathi
|
Jun 29, 2025 |
|
Navigating Drug Accessibility in Cancer Care
|
Jun 20, 2025 |
|
The 'HemOnc Pulse Live' Controversies in Aggressive NHL
|
Jun 05, 2025 |
|
Inside the War on Myeloid Malignancies: Early Clues & Bold Innovations
|
May 23, 2025 |
|
'The HemOnc Pulse' Live 2025: Controversies in MDS
|
May 09, 2025 |
|
Redirected Strategy: Tal and TEC in the Myeloma Mix
|
May 02, 2025 |
|
Dr. Usmani Highlights Myeloma Presentations from SOHO 2024
|
Nov 20, 2024 |
|
Covering MDS Updates at SOHO 2024 With Dr. Venugopal
|
Nov 01, 2024 |
|
AML News From SOHO 2024 With Dr. Daver
|
Oct 11, 2024 |
|
Dr. Shadman Shares SOHO 2024 Data On CLL
|
Sep 27, 2024 |
|
Dr. Bose on MPN Highlights From SOHO 2024
|
Sep 17, 2024 |
|
Part Two: The Question of MRD in CLL Therapy
|
Aug 22, 2024 |
|
Dr. Osman on Identifying and Treating High-Risk MDS
|
Aug 09, 2024 |
|
Dr. Rami Komrokji on Trends in Real-World MDS Care
|
Jul 25, 2024 |
|
Part One: The Question of MRD in CLL Therapy
|
Jul 18, 2024 |
|
‘The HemOnc Pulse’ Live: Unanswered Questions in T-Cell Lymphoma
|
May 30, 2024 |
|
‘The HemOnc Pulse’ Live 2024: Is it Time for New Endpoints in MPN?
|
May 29, 2024 |
|
Unpacking Bispecifics at ‘The HemOnc Pulse’ Live Meeting
|
May 24, 2024 |
|
'The HemOnc Pulse' Live: Unanswered Questions in Treating DLBCL
|
May 23, 2024 |
|
‘The HemOnc Pulse’ Live 2024: Unanswered Questions in CML Treatment
|
May 21, 2024 |
|
‘The HemOnc Pulse’ Live: What Are the Unanswered Questions in ALL?
|
May 21, 2024 |
|
Discussing the Role of MRD in CLL With Talal Hilal, MD
|
May 16, 2024 |
|
‘The HemOnc Pulse’ Live 2024: How Is Hodgkin Lymphoma Treated?
|
May 14, 2024 |
|
Unanswered Questions in MDS at ‘The HemOnc Pulse’ Live 2024 in Chicago
|
May 13, 2024 |
|
‘The HemOnc Pulse Live’ in Chicago: Fellows Discuss Choosing a Career Path in Hematology Oncology
|
May 08, 2024 |
|
“The HemOnc Pulse” Live 2024 in Chicago: CAR-T Unanswered Questions
|
May 04, 2024 |
|
"The HemOnc Pulse" Live 2024 in Chicago: AML Unanswered Questions
|
May 04, 2024 |
|
What are the Controversies Surrounding MRD in Blood Cancers?
|
Apr 25, 2024 |
|
HMAs Are ‘Cornerstone’ of High-Risk MDS Treatment, Says Jamile Shammo, MD
|
Apr 10, 2024 |
|
Krish Patel, MD, Talks Glofitamab, Other Novel Therapies in DLBCL
|
Apr 04, 2024 |
|
Aaron Goodman, MD, Tells Us the 'Crux' of Castleman Disease
|
Apr 02, 2024 |
|
Is MRD Negativity the New Benchmark in ALL Treatment Strategies?
|
Mar 14, 2024 |
|
Part Two: Drs. Dahiya, Spiegel Return to Discuss 'Black Box' Warning on CAR-T Therapies
|
Feb 29, 2024 |
|
Dr. Coombs Spotlights Recent CHIP Updates
|
Feb 15, 2024 |
|
Drs. Dahiya, Spiegel Discuss CAR-T Secondary Malignancies Risk
|
Feb 08, 2024 |
|
Aditi Shastri, MD: Clinicians Need to ‘Come Together’ on TP53-Mutated MDS
|
Jan 18, 2024 |
|
What It Takes to Harmonize the World’s Hodgkin Lymphoma Data
|
Jan 04, 2024 |
|
Dr. Usmani Discusses Perseus, IsKia, Data Plus More Myeloma Updates
|
Dec 18, 2023 |
|
Dr. Venugopal Offers Her Thoughts on the Latest MDS News
|
Dec 18, 2023 |
|
Jerald Radich, MD: AML Abstracts to Keep an Eye on at ASH 2023
|
Dec 17, 2023 |
|
Inside the FDA ODAC ’Yes’ Vote to Polivy
|
Nov 30, 2023 |
|
Kami Maddocks, MD, on the Shocking Ibrutinib Withdrawal
|
Nov 16, 2023 |
|
Jorge Cortes, MD, on Why Balance Is Key in CML Therapy
|
Nov 02, 2023 |
|
What Are the Top Questions in ALL?
|
Oct 19, 2023 |
|
The ABCs of MM Treatment According to Rafael Fonseca, MD
|
Oct 05, 2023 |
|
The Post-POLARIX Trial Era: Polatuzumab Vedotin Shifts DLBCL Treatment
|
Sep 14, 2023 |
|
Dr. Garcia-Manero on the Data Behind the Luspatercept Approval
|
Sep 13, 2023 |
|
Mazyar Shadman, MD, MPH, Reports the Latest BTKi News in CLL
|
Aug 24, 2023 |
|
Bhavana Bhatnagar, MD, on the Molecular Revolution in AML
|
Aug 10, 2023 |
|
Do Venetoclax Combinations Trump Chemotherapy in Frontline CLL Treatment?
|
Jul 27, 2023 |
|
Why Grzegorz Nowakowski, MD, Says There’s a ‘Revolution’ in LBCL Therapy
|
Jul 13, 2023 |
|
An Expert’s Look into the World of Rare Blood Cancers
|
Jun 29, 2023 |
|
The Logistics of CAR-T in Hematologic Malignancies
|
Jun 15, 2023 |
|
Abi Vijenthira, MD, and Anca Prica, MD, on Why Certain DLBCL Therapies May Not Be Cost Effective
|
May 18, 2023 |
|
Sagar Lonial, MD, FACP, on Why This MRD Approach Is ’Premature’ in MM
|
May 04, 2023 |
|
Alan Skarbnik, MD, Gives the Lowdown on Treating Patients with Follicular Lymphoma
|
Apr 20, 2023 |
|
Amer Zeidan, MBBS, MHS, on the Evolution of AML Classification, Treatment
|
Apr 06, 2023 |
|
What Is the Cost-Effectiveness of Pola-R-CHP in DLBCL?
|
Mar 23, 2023 |
|
Graham Collins, MBBS, on New Agents, Prognostic Models in Hodgkin Lymphoma
|
Mar 09, 2023 |
|
What Keeps Michael Bishop, MD, Up at Night When it Comes to CAR-T?
|
Feb 23, 2023 |
|
Laurie H. Sehn, MD, MPH, on the Game-Changing Bispecifics in Follicular Lymphoma
|
Feb 09, 2023 |
|
Sanam Loghavi, MD, Tells Us Why 2022 was a Major Year for MDS
|
Jan 26, 2023 |
|
Elizabeth Brem, MD, on Which CLL Abstract From ASH 2022 Can’t Be Ignored
|
Jan 12, 2023 |
|
Ruben Mesa, MD, Discusses MPN Updates at ASH 2022 and the Evolution of the Disease
|
Dec 29, 2022 |
|
Drs. Hagop Kantarjian and Elias Jabbour Discuss Important AML, ALL Updates From ASH 2022
|
Dec 14, 2022 |